Health
Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine – News-Medical.Net
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being…
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The vaccine comprises a recombinant adenovirus serotype 26 (Ad26) vaccine vector expressing a stabilized form of the SARS-CoV-2 spike antigen that the…
-
General23 hours agoKim Kardashian not deterred by bar failure
-
Business18 hours agoMacquarie tips more than 20% upside for this ASX mining stock
-
Noosa News16 hours agoSchools ban e-bikes | Noosa Today
-
Noosa News15 hours agoNRL legend Trevor Gillmeister charged with assaulting police officer at Brisbane pub